Startup profile · funding coverage
Elegen funding, valuation and investors
Next-generation cell-free DNA synthesis for genetic medicine manufacturing.
Keep track of Elegen
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$35M · May 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$35M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · San Carlos, California
Overview
Elegen manufactures next-generation cell-free DNA using its ENFINIA platform — accelerating GMP-compliant DNA production for mRNA vaccines, cell therapy, and CRISPR workflows. Raised $35M Series B in May 2024 led by Triatomic Capital with 8VC and a16z Bio+Health re-upping to expand clinical manufacturing capacity.
Why Elegen is interesting
Elegen speeds GMP-compliant DNA production for genetic medicine — 8VC joined a16z in its $35M Series B in 2024.
Product & use cases
ENFINIA platform produces long, accurate, GMP-grade cell-free DNA — critical input for mRNA, cell therapy, and gene editing manufacturing.
- GMP DNA production for mRNA vaccine manufacturing
- Cell therapy construct production
- CRISPR guide RNA template synthesis at scale
Key facts
- Series B (May 2024): $35M led by Triatomic; 8VC, a16z Bio+Health (Businesswire)
- ENFINIA cell-free DNA synthesis platform
Funding history (newest first)
Series B
2024-05 $35M- Triatomic Capital (lead)
- 8VC (participant)
- Andreessen Horowitz (participant)
Source: https://elegenbio.com/news/elegen-raises-35-million-in-series-b/
Investors in our directory
Funds linked from Elegen's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Cell-free synthesis speed and length vs. traditional plasmid fermentation — reducing manufacturing bottlenecks.
DNA synthesis is critical infrastructure for genetic medicine boom. Elegen competes on GMP compliance and production speed for long constructs.
-
Twist Bioscience direct
Synthetic DNA manufacturer at scale.
-
GenScript incumbent
Gene synthesis services.
-
Integrated DNA Technologies incumbent
DNA oligo and gene synthesis.
-
In-house pharma manufacturing incumbent
Large pharma internal DNA production.
Notable stories
- Elegen expanded into clinical manufacturing with Series B — betting DNA synthesis bottlenecks will constrain genetic medicine scale-up (Businesswire, 2024).
Industries
FAQs about Elegen
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.